Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd

₹ 623 -1.57%
24 Jun - close price
About

Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]

Key Points

Business Overview:[1]
Aarti Pharmalabs Limited (APL) formerly known as Aarti Organics was established in 1984 as a WOS of Aarti Industries Limited. Got demerged in Oct,22 into a separately listed entity.
Co. is an internationally recognized manufacturer of generic API & Intermediates, Xanthine derivatives and offers CDMO/CMO services. Company has 6 manufacturing plants and 3 R&D centres.

  • Market Cap 5,650 Cr.
  • Current Price 623
  • High / Low 653 / 320
  • Stock P/E 28.2
  • Book Value 179
  • Dividend Yield 0.32 %
  • ROCE 16.4 %
  • ROE 13.1 %
  • Face Value 5.00

Pros

Cons

  • Company has a low return on equity of 13.6% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
365 373 404 359 374 358 356 373 415
296 294 324 287 297 281 282 285 307
Operating Profit 68 79 80 73 77 77 74 88 107
OPM % 19% 21% 20% 20% 21% 21% 21% 24% 26%
3 0 1 0 0 5 0 0 6
Interest 4 4 6 5 6 4 4 4 4
Depreciation 12 12 15 15 14 15 16 17 17
Profit before tax 54 62 61 53 57 62 54 67 91
Tax % 17% 24% 25% 27% 30% 23% 22% 29% 31%
45 47 46 39 40 48 42 48 63
EPS in Rs 4.25 4.41 5.26 4.61 5.32 6.95
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024
0 941 1,511 1,502
0 761 1,203 1,156
Operating Profit 0 180 309 346
OPM % 19% 20% 23%
0 3 1 11
Interest 0 11 20 17
Depreciation 0 37 56 66
Profit before tax 0 134 233 275
Tax % 20% 26% 27%
0 107 172 201
EPS in Rs 18.95 22.14
Dividend Payout % 0% 11% 14%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -1%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 17%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 61%
Return on Equity
10 Years: %
5 Years: %
3 Years: 14%
Last Year: 13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 0 0 45 45
Reserves -0 1,284 1,393 1,576
0 327 208 272
0 215 317 404
Total Liabilities 0 1,827 1,963 2,297
0 701 848 1,012
CWIP 0 187 102 78
Investments 0 40 43 62
0 898 970 1,145
Total Assets 0 1,827 1,963 2,297

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024
0 -65 229 184
0 -134 -116 -184
0 255 -157 4
Net Cash Flow 0 56 -43 4

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 118 87 109
Inventory Days 359 280 283
Days Payable 106 114 124
Cash Conversion Cycle 371 253 268
Working Capital Days 263 168 202
ROCE % 18% 16%

Shareholding Pattern

Numbers in percentages

4 Recently
Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
45.98% 45.98% 46.30% 46.46% 46.46%
7.69% 7.43% 8.45% 8.17% 8.33%
13.68% 10.65% 10.51% 9.91% 9.97%
0.01% 0.01% 0.01% 0.01% 0.01%
32.64% 35.92% 34.73% 35.45% 35.24%
No. of Shareholders 2,76,6642,58,2392,26,2862,15,7962,04,122

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents